The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100. Predicted molecular weight: 30 kDa.
Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. The catalytic inactive RNA exosome core complex of 9 subunits (Exo-9) is proposed to play a pivotal role in the binding and presentation of RNA for ribonucleolysis, and to serve as a scaffold for the association with catalytic subunits and accessory proteins or complexes. EXOSC8 binds to ARE-containing RNAs.
Immunocytochemistry/ Immunofluorescence - Anti-EXOSC8 antibody (ab82290)This image is courtesy of an anonymous Abreview
Immunofluorescence analysis of Human skin fibroblasts, staining EXOSC8 with ab82290.
Cells were fixed with paraformaldehyde, permeabilized with 0.1 % Triton-X-100 and blocked with 5% serum for 30 minutes at 25°C. Samples were incubated with primary antibody (1/200 in 5% serum) for 3 hours at 25°C. An Cy2®-conjugated donkey anti-rabbit polyclonal IgG (1/500) was used as the secondary antibody.